Approval · Notice of Compliance 25353 · 2021
NEXTSTELLIS: Notice of Compliance 25353
Issued March 5, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25353
- Date
- March 5, 2021
- Company
- Searchlight Pharma Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEXTSTELLIS | 02513218 | Marketed |
Medicinal ingredients
- DROSPIRENONE 3 MG per TAB
- ESTETROL MONOHYDRATE 15 MG per TAB